Mechanism
CJC-1295 is a synthetic analog of the first 29 amino acids of growth-hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor to prompt the body’s own GH release, rather than supplying GH directly.
| Mechanism | Detail |
|---|---|
| GHRH receptor agonism | Binds GHRH receptors on pituitary somatotrophs, triggering release of endogenous GH into circulation. |
| Stabilizing substitutions | Four amino-acid modifications to native GRF 1–29 slow enzymatic breakdown, giving a longer window than raw GHRH while still clearing within roughly half an hour. |
| Pulsatile, not flat | Amplifies the body’s natural GH pulses instead of clamping GH at a constant level — a pattern preserved even under sustained stimulation in the early studies. |
| Downstream IGF-1 | Elevated GH drives hepatic IGF-1, the mediator behind most claimed anabolic and recovery effects. |
| DAC is a different molecule | The Drug Affinity Complex (DAC) version binds serum albumin for a multi-day half-life. The no-DAC “Mod GRF 1–29” sold today does not, and behaves very differently. |
Evidence Summary
Direct human evidence for the no-DAC form is thin. The most-cited human data — the 2006 Teichman and Ionescu reports — studied the long-acting DAC conjugate, not the short-acting Mod GRF 1–29 that dominates the research-chemical market.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| GH elevation | Dose-dependent GH rises | Human (DAC form) | Established for the DAC conjugate; extrapolated to no-DAC by mechanism. |
| IGF-1 elevation | Sustained multi-day IGF-1 rise | Human (DAC form) | The multi-day duration reflects DAC’s albumin binding, not the no-DAC form. |
| Preserved GH pulsatility | GH stayed pulsatile | Human (DAC form) | Ionescu & Frohman (2006) — again in the DAC version. |
| Body composition / recovery | No controlled human trials | Unproven | Claims rest on the GH→IGF-1 rationale, not outcome data. |
| Long-term safety | No long-duration human data | Unknown | Sustained GH/IGF-1 elevation carries theoretical risk. |
| No-DAC form specifically | Essentially no dedicated human trials | Evidence gap | Most marketing borrows DAC-form data. |
| Human clinical trials | A few small early-phase studies | Human | Development did not progress to pivotal trials. |
Divergence — What This Means
The DAC / no-DAC confusion drives the whole gap.
Vendors routinely sell short-acting “Mod GRF 1–29” under the CJC-1295 name while quoting the 6-to-8-day half-life and the 2006 human results — both of which belong to the long-acting DAC conjugate. In practice the no-DAC peptide clears in roughly half an hour, which is why community protocols call for multiple daily injections.
Community discussion also treats GH and IGF-1 elevation as settled proof of fat loss, muscle gain, and anti-aging benefit. The honest position is narrower: the compound reliably raises GH and IGF-1 in early studies, but no controlled trial has shown those biomarker moves translate into the outcomes users are chasing.
Community discussion also treats GH and IGF-1 elevation as settled proof of fat loss, muscle gain, and anti-aging benefit. The honest position is narrower: the compound reliably raises GH and IGF-1 in early studies, but no controlled trial has shown those biomarker moves translate into the outcomes users are chasing.
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Typical unit dose
~100 mcg
community reference, no-DAC form
Frequency
1–3×/day
reflects the ~30-min half-life
Route
Subcutaneous
as reported in community protocols
Common timing
Pre-sleep / fasted
to align with natural GH pulses
Figures are community and anecdotal references only, not medical guidance. There is no approved human dose for CJC-1295; it is sold research-use-only and is not for human consumption. Reported protocols vary widely and are not validated by clinical trials.
Safety Profile
Short-term tolerability in the small 2006 studies was reasonable, with injection-site reactions the most common complaint. Longer-term and no-DAC-specific safety data are effectively absent.
Animal / preclinical — signals observed
Injection-site redness, itching, or irritation
Flushing or a warm sensation after dosing
Headache and transient dizziness
Water retention / mild edema (GH-related)
What is not known (human)
Effects of sustained GH/IGF-1 elevation over months to years
Long-term metabolic impact (insulin sensitivity, glucose)
Theoretical risk of promoting existing occult tumor growth via IGF-1
Safety of the no-DAC form specifically, which lacks dedicated trials
Interactions with other secretagogues in common stacks
Not medical advice. CJC-1295 is not an approved drug. Sold for research use only; not for human consumption.
Regulatory Status — Updated July 2026
Named for reconsideration, but not yet reviewed
CJC-1295 was not part of the July 23–24, 2026 PCAC meeting. It was among the peptides HHS signaled for reconsideration in early 2026, but it has not been formally reviewed or voted on, and no PCAC recommendation exists for it. Treat its status as pending a future round. It remains unapproved by the FDA and is sold research-use-only. Track current status →
Where to Source
Source research-grade CJC-1295
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source CJC-1295.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
No. CJC-1295 was not on the agenda for the July 23–24, 2026 PCAC meeting and was not voted on. It was named among peptides HHS flagged for reconsideration earlier in 2026, but no formal review or recommendation has happened yet. Its status is pending a future round.
The DAC (Drug Affinity Complex) version binds serum albumin, stretching its half-life to roughly 6–8 days. The no-DAC form — correctly called Modified GRF 1–29 — lacks that modification and clears in about 30 minutes, which is why protocols use several small daily injections. Most product sold as “CJC-1295” is actually the no-DAC form.
Some, but less than marketing implies. The most-cited human studies (2006) showed dose-dependent GH and IGF-1 increases — but they studied the long-acting DAC conjugate, not the short-acting no-DAC form on the market. There are no large efficacy RCTs for either version.
No controlled human trial has shown that. It reliably raises GH and IGF-1 in early studies, and users infer body-composition benefit from that, but the biomarker-to-outcome link has not been demonstrated in trials.
Compare CJC-1295